AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%
Last update at 2024-04-24T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -165.75700M | -106.93100M | -82.16900M | -32.96800M | -19.27000M |
| Minority interest | - | - | - | - | - |
| Net income | -171.84900M | -106.63000M | -82.00800M | -32.33500M | -19.27000M |
| Selling general administrative | 68.76M | 54.23M | 24.30M | 7.80M | 5.40M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 0.35M | - | 0.00002M | - | 0.00000M |
| Reconciled depreciation | 0.33M | 0.30M | 0.19M | 0.16M | 0.02M |
| Ebit | -159.64500M | -107.23200M | -82.48500M | -33.60100M | -20.65400M |
| Ebitda | -157.54400M | -106.93500M | -82.29700M | -34.07800M | -20.63700M |
| Depreciation and amortization | 2.10M | 0.30M | 0.19M | -0.47700M | 0.02M |
| Non operating income net other | 2.10M | 0.04M | - | - | - |
| Operating income | -159.64500M | -106.93500M | -82.29700M | -33.60100M | -19.96200M |
| Other operating expenses | 160.02M | 106.94M | 82.30M | 33.60M | 19.96M |
| Interest expense | 8.21M | 0.04M | 0.03M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 2.53M | 0.04M | - | 0.63M | 0.69M |
| Net interest income | -5.68500M | 0.00400M | 0.13M | - | 0.69M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 6.09M | -0.30100M | -0.16100M | -0.63300M | 0.69M |
| Total revenue | 0.38M | 0.00000M | 0.00002M | 0.00000M | 0.00000M |
| Total operating expenses | 160.00M | 106.94M | 82.30M | 33.60M | 19.96M |
| Cost of revenue | 0.02M | - | - | - | 0.00000M |
| Total other income expense net | -6.11200M | 0.00400M | 0.13M | 0.63M | 0.69M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -165.75700M | -106.93100M | -82.32400M | -32.96800M | -19.27000M |
| Net income applicable to common shares | -165.75700M | -106.93100M | -82.16900M | -32.96800M | -19.27000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 205.85M | 239.44M | 219.94M | 36.39M | 43.55M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.84M | 0.96M | 3.95M | 1.68M | 0.49M |
| Total liab | 129.08M | 17.77M | 13.24M | 9.50M | 4.66M |
| Total stockholder equity | 76.78M | 221.67M | 206.70M | 26.89M | 38.89M |
| Deferred long term liab | 2.34M | - | - | - | - |
| Other current liab | 22.35M | 11.70M | 0.24M | 3.52M | 3.06M |
| Common stock | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -411.54500M | -245.78800M | -138.85700M | -56.68800M | -23.72000M |
| Other liab | 2.34M | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 0.93M | 0.09M | 1.60M | 0.05M | 0.05M |
| Cash | 193.72M | 232.97M | 213.12M | 32.43M | 42.56M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 32.90M | 16.67M | 11.84M | 8.47M | 4.66M |
| Current deferred revenue | - | - | 7.39M | - | - |
| Net debt | -99.56900M | -231.57000M | -211.48400M | -31.39700M | -42.56500M |
| Short term debt | 0.32M | 0.29M | 0.24M | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 94.16M | 1.40M | 1.64M | 1.03M | - |
| Other stockholder equity | 488.29M | 467.43M | 345.53M | 83.56M | 62.61M |
| Property plant equipment | 1.08M | 1.29M | 1.27M | 2.23M | 0.33M |
| Total current assets | 202.87M | 232.97M | 217.06M | 34.11M | 43.17M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 76.78M | 221.67M | 206.70M | 26.89M | 38.89M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.25M | - | - | - | 0.12M |
| Long term debt | 93.05M | - | - | - | - |
| Inventory | 1.99M | - | - | - | - |
| Accounts payable | 10.23M | 4.68M | 3.98M | 4.95M | 1.60M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -0.17400M | -0.01800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -411.54500M | -245.78800M | -138.85700M | -56.68800M | -23.72000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.93M | 3.93M | 0.09M | 0.05M | 0.05M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2.98M | 6.47M | 2.87M | 2.29M | 0.38M |
| Capital lease obligations | 1.10M | 1.40M | 1.40M | 1.03M | - |
| Long term debt total | 93.05M | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.13900M | -0.44500M | -0.31600M | -0.87000M | -0.34000M |
| Change to liabilities | 16.83M | 4.85M | 3.03M | 3.58M | 3.20M |
| Total cashflows from investing activities | -0.13900M | -0.44500M | -0.31600M | -0.87000M | -0.34000M |
| Net borrowings | 95.95M | 98.60M | 98.60M | 0.18M | -0.37100M |
| Total cash from financing activities | 96.24M | 102.45M | 247.36M | 18.01M | 55.53M |
| Change to operating activities | 0.68M | 0.13M | -2.01300M | -1.19000M | -0.53900M |
| Net income | -165.75700M | -106.93100M | -82.16900M | -32.96800M | -19.27000M |
| Change in cash | -39.24300M | 19.85M | 180.69M | -10.13900M | 41.68M |
| Begin period cash flow | 232.97M | 213.12M | 32.43M | 42.56M | 0.89M |
| End period cash flow | 193.72M | 232.97M | 213.12M | 32.43M | 42.56M |
| Total cash from operating activities | -135.34100M | -82.15300M | -66.35000M | -27.28000M | -13.50900M |
| Issuance of capital stock | 0.00000M | 100.99M | 255.78M | 17.81M | 56.51M |
| Depreciation | 0.33M | 0.30M | 0.19M | 0.16M | 0.02M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.98500M | -1.98500M | -1.98500M | -1.98500M | - |
| Change to account receivables | -0.24800M | -0.24800M | -0.24800M | -0.24800M | - |
| Sale purchase of stock | 0.28M | 102.45M | -9.02400M | 17.81M | 56.51M |
| Other cashflows from financing activities | 96.24M | 1.45M | 0.60M | 0.20M | -0.61500M |
| Change to netincome | 18.55M | 19.50M | 14.61M | 3.14M | 3.08M |
| Capital expenditures | 0.14M | 0.45M | 0.32M | 0.87M | 0.34M |
| Change receivables | -0.24800M | - | - | - | - |
| Cash flows other operating | -3.92700M | 0.13M | -2.01300M | -1.19000M | -0.53900M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -39.24300M | 19.85M | 180.69M | -10.13900M | 41.68M |
| Change in working capital | 10.67M | 4.98M | 1.02M | 2.39M | 2.66M |
| Stock based compensation | 17.34M | 19.45M | 14.61M | 3.14M | 3.08M |
| Other non cash items | 2.08M | 0.05M | -178.56400M | 15.26M | -37.29600M |
| Free cash flow | -135.48000M | -82.59800M | -66.66600M | -28.15000M | -13.84900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics Inc |
-0.26 8.75% | 2.71 | - | - | 70.00 | 3.97 | 77.78 | -0.4867 |
| NVO Novo Nordisk A/S |
-2.48 1.93% | 126.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.58 1.23% | 126.80 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.15 1.02% | 400.76 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-0.61 0.67% | 90.10 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
555 Long Wharf Drive, New Haven, CT, United States, 06511
| Name | Title | Year Born |
|---|---|---|
| Dr. Vimal D. Mehta Ph.D. | Founder, CEO, Pres, & Director | 1961 |
| Dr. Frank D. Yocca Ph.D. | Sr. VP & Chief Scientific Officer | 1956 |
| Mr. Javier Rodriguez | Sr. VP, Chief Legal Officer & Corp. Sec. | 1972 |
| Dr. Krishnan Nandabalan Ph.D. | Chief Digital Officer ?& Director | 1963 |
| Mr. Richard I. Steinhart MBA | Sr. VP & CFO | 1957 |
| Ms. Mary Coleman | VP of Investment Relations | NA |
| Dr. Iris Francesconi Ph.D. | Sr. VP of Marketing, Market Research & Commercial Assessments | NA |
| Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P. | Sr. VP & Chief Medical Officer | 1969 |
| Dr. Cedric Burg | VP and Head of Global Clinical Operations & Project Management | NA |
| Dr. Chetan D. Lathia Ph.D. | Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...